Treatment Decision-Making for Complex Patients With HIV: Drug Resistance, Adverse Effects, Comorbidities and Polypharmacy, and Overcoming Barriers to Equitable Care

Program Description

This activity was originally presented at APhA2024 in Orlando, Florida.

Antiretroviral therapy (ART) for people living with HIV can be complex, with effectiveness depending on strict adherence to oral dosing regimens. Multidrug resistance may occur with long-term ART, requiring new drug therapy. This is a persistent public health problem. Pharmacists must be knowledgeable on the disparities and challenges of caring for people living with HIV. New and emerging ARTs can impact practice guideline recommendations. This activity will educate pharmacists on the complexities of managing HIV to ensure proper patient treatment optimization, adherence, and address health disparities and HIV-related complications.

Target Audience: Health System Pharmacist, Retail Pharmacist

Type of Activity: Application
Release date: April 1, 2024
Expiration date: June 24, 2025

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the complexities between antiretroviral therapy (ART), comorbidities, and HIV-related complications in people living with HIV
• Explore the resistance, safety profiles, and potential drug interactions associated with different ARTs
• Analyze the efficacy and safety of new and emerging ARTs for the treatment of HIV
• Explain strategies for comprehensive patient education on disease management, treatment options, and adherence

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-24-062-H02-P. The activity is available for CE credit through June 24, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP, has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: Research funding through Merck Investigator Studies Program at the University of New Mexico

Consultant: ID/HIV Consultant for Wolters-Kluwer (Lexicomp)

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Larry York, PharmD, BCIDP, BCPS, AAHIVP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Namissa-Buszka, PharmD, BCPS, CHCP; Adam C Welch, PharmD, MBA, FAPhA; Angelica Archibald; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms